Volume 29, Number 6—June 2023
Research Letter
Manifestations and Management of Trimethoprim/Sulfamethoxazole–Resistant Nocardia otitidiscaviarum Infection
Table
Drug | Sensitivity |
---|---|
Amikacin | Sensitive |
Amoxicillin/clavulanate | Resistant |
Cefepime | Resistant |
Ceftriaxone | Resistant |
Ciprofloxacin | Intermediate |
Clarithromycin | Sensitive |
Doxycycline | Resistant |
Imipenem | Intermediate |
Linezolid | Sensitive |
Minocycline | Intermediate |
Moxifloxacin | Sensitive |
Tobramycin | Intermediate |
Trimethoprim/sulfamethoxazole | Resistant |
Page created: April 06, 2023
Page updated: May 18, 2023
Page reviewed: May 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.